A single center experience with bone marrow transplantation for high risk neuroblastoma.
Ladenstein
R
R
Coordination Center EBMT Registry, Lyon, France.
Lasset
C
C
Bouffet
E
E
Brunat-Mentigny
M
M
Biron
P
P
Philip
I
I
Chauvin
F
F
Philip
T
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D016190:Carboplatin / Q000008:administration & dosage; D002330:Carmustine / Q000008:administration & dosage; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007223:Infant; D008297:Male; D009447:Neuroblastoma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D012074:Remission Induction; D012086:Reoperation; D015996:Survival Rate; D013713:Teniposide / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D009944:Organoplatinum Compounds; C055423:didimethylsulfoxide dichloroplatinum(II); D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D013713:Teniposide; D016190:Carboplatin; D002330:Carmustine